By a News Reporter-Staff News Editor at Vaccine Weekly -- Data detailed on Immunology have been presented. According to news reporting originating in Buffalo, New York, by NewsRx journalists, research stated, "Vaccine strategies aimed at generating CD8(+) T cell memory responses are likely to show augmented efficacy against chronic challenges like tumor. The abundance in variety of memory CD8(+) T cells behooves development of vaccine strategies that generate distinct memory responses and evaluate them for tumor efficacy."
The news reporters obtained a quote from the research from Roswell Park Cancer Institute, "In this study, we demonstrate the ability of a variety of rapamycin treatment regimens to regulate virus vaccination-induced CD8(+) T cell memory responses and tumor efficacy. Strikingly, a short course of high-dose, but not low-dose, rapamycin treatment transiently blocks viral vaccination-induced mammalian target of rapamycin activity in CD8(+) T cells favoring persistence and Ag-recall responses over type 1 effector maturation; however, prolonged high-dose rapamycin administration abrogated memory responses. Furthermore, a short course of high-dose rapamycin treatment generated CD8(+) T cell memory responses that were independent of IL-15 and IL-7 and were programmed early for sustenance and greater tumor efficacy."
According to the news reporters, the research concluded: "These results demonstrate the impact a regimen of rapamycin treatment has on vaccine-induced CD8(+) T cell responses and indicates that judicious application of rapamycin can augment vaccine efficacy for chronic challenges."
For more information on this research see: Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. Journal of Immunology, 2012;188(7):3080-7. (The American Association of Immunologists - www.aai.org; Journal of Immunology - www.jimmunol.org)
Our news correspondents report that additional information may be obtained by contacting Q. Li, Dept. of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States (see also Immunology).
Keywords for this news article include: Buffalo, New York, Vaccines, Immunology, Vaccination, Immunization, United States, Biological Products, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .